Immunogenicity of HER2 vaccine containing<i> p</i>-nitrophenylalanine

HE Yu; TIAN Hong; DAI Xin; YAO Wenbing; GAO Xiangdong

doi:10.11665/j.issn.1000-5048.20180317

Journal of China Pharmaceutical University > 2018 > 49(3): 369-375. > DOI: 10.11665/j.issn.1000-5048.20180317

HE Yu, TIAN Hong, DAI Xin, YAO Wenbing, GAO Xiangdong. Immunogenicity of HER2 vaccine containing p-nitrophenylalanine[J]. Journal of China Pharmaceutical University, 2018, 49(3): 369-375. DOI: 10.11665/j.issn.1000-5048.20180317

Citation:

PDF (1659 KB)

Immunogenicity of HER2 vaccine containing p-nitrophenylalanine

More Information

Graphical Abstract

Abstract

Abstract

In order to delete the immune tolerance of self-protein HER2 and produce an efficient immune response, the genetic code expansion technique was employed to introduce the immunogenic amino acid p-nitrophenylalanine into the position 5, 26 and 79 of the HER2 fragment and HER2 mutants containing p-nitrophenylalanine were obtained. Prototype and mutant HER2 molecules with a purity of more than 95% were obtained through a nickel affinity column. Immunogenicity analysis of the HER2 vaccine showed that pNO₂Phe⁷⁹HER2 was able to produce high titer cross-reactive antibodies in C57BL/6 mice and that the mouse antisera could recognize SKBR-3 cells with intact HER2 receptor extracellular domain and cleave HER2 highly expressed HER2+B16F10 cells through ADCC effect. These findings suggested that pNO₂Phe⁷⁹HER2 which incorporates p-nitrophenylalanine could be used as a tumor vaccine candidate targeting HER2.
- HER2,
- p-nitrophenylalanine,
- immunogenicity

FullText(HTML)

References (17)

References

[1]	Liu Y,el-Ashry D,Chen D,et al.MCF-7 breast cancer cells ove-rexpressing transfected cerbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo[J].Breast Cancer Res Treat,1995,34(2):97-117.
[2]	Tsang R,Finn R.Beyond trastuzumab:novel therapeutic strategies in HER2-positive metastatic breast cancer [J].Br J Cancer,2012,106(1):6-13.
[3]	De Santes K,Slamon D,Anderson SK,et al.Radiolabeled antibody targeting of the HER-2/neu oncoprotein [J].Cancer Res,1992,52(7):1916-1923.
[4]	Spector NL,Xia W,Burris H,et al.Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies [J].J Clin Oncol,2005,23(11):2502-2512.
[5]	Earl HM,Vallier AL,Dunn J,et al.Trastuzumab-associated cardiac events in the Persephone trial [J].Br J Cancer,2016,115(12):1462-1470.
[6]	Eryilmaz A,Demirci B,Gunel C,et al.Evaluation of lapatinib and trastuzumab for ototoxic effects [J].J Int Adv Otol,2015,11(3):207-211.
[7]	Spector NL,Xia W,Burris H,et al.Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies [J].J Clin Oncol,2005,23(11):2502-2512.
[8]	Costa RLB,Soliman H,Czerniecki BJ.The clinical development of vaccines for HER2+ breast cancer:current landscape and future perspectives [J].Cancer Treat Rev,2017,61:107-115.
[9]	Tabi Z,Man S.Challenges for cancer vaccine development [J].Adv Drug Deliv Rev,2006,58(8):902-915.
[10]	Dalgleish AG.Therapeutic cancer vaccines:why so few randomised phase III studies reflect the initial optimism of phase II studies [J].Vaccine,2011,29(47):8501-8505.
[11]	Grunewald J,Hunt GS,Dong L,et al.Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids [J].Proc Natl Acad Sci U S A,2009,106(11):4337-4342.
[12]	Dai HT,Tian H,Huang J,et al.Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice [J].J China Pharm Univ(中国药科大学学报),2017,48(4):483-489.
[13]	Kessel C,Nandakumar KS,Peters FB,et al.A single functional group substitution in C5a breaks B cell and T cell tolerance and protects against experimental arthritis [J].Arthritis Rheumatol,2014,66(3):610-621.
[14]	Cai D,Tian H,Yao WB.Molecular dynamics simulation and analysis of BAFF which is incorporated with p-nitro-L-phenylalanine[J].J China Pharm Univ(中国药科大学学报),2017,48(2):227-232.
[15]	Gauba V, Grunewald J, Gorney V, et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids [J].Proc Natl Acad Sci U S A,2011,108(31):12821-12826.
[16]	Kageyama S, Kitano S, Hirayama M, et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel [J].Cancer Sci,2008,99(3):601-607.
[17]	Hardy LL, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated analog 3′-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells [J].J Immunol,2008,180(9):5956-5962.

[1]	WU Lingxi, DU Yixuan, GAO Xiangdong. Inhibitory effect of IL-27 on the overactivation of microglia[J]. Journal of China Pharmaceutical University, 2024, 55(6): 801-808. DOI: 10.11665/j.issn.1000-5048.2024022702
[2]	CUI Tao, WU Weidang, CI Xiaoyan, LI Wei, GUO Chuanmin, XU Jing, YI Xiulin, LIU Changxiao. Evaluation of tolerance and pharmacodynamics of nano-micelle irinotecan formulation[J]. Journal of China Pharmaceutical University, 2019, 50(2): 175-179. DOI: 10.11665/j.issn.1000-5048.20190207
[3]	YUE Juanjuan, CUI Hanyue, WANG Hui, YE Bin, CHEN Dingding. Protective effects of losartan potassium on 5/6 nephrectomy-induced chronic heart failure in rats[J]. Journal of China Pharmaceutical University, 2016, 47(6): 734-739. DOI: 10.11665/j.issn.1000-5048.20160617
[4]	JIANG Yuqiu, TANG Qiaofei, ZHANG Shuang, YAN Zhiyong. Combined effects of gallic acid and ciprofloxacin on the murine chronic rhinosinusitis model in mice[J]. Journal of China Pharmaceutical University, 2015, 46(5): 600-604. DOI: 10.11665/j.issn.1000-5048.20150514
[5]	CHEN Lu, LI Jiajie, PAN Cailong, ZHOU Danli, LIU Wentao, ZHANG Guangqin. Tetramethylpyrazine attenuates morphine tolerance through suppressing spinal microglia activation in mice[J]. Journal of China Pharmaceutical University, 2015, 46(2): 230-234. DOI: 10.11665/j.issn.1000-5048.20150216
[6]	WANG Yu, ZHAO Li, MIAO Hanchi, LI Zhiyu, GUO Qinglong. Apoptosis induction of oroxylin A in human chronic myelogenous leukemia cell line K562[J]. Journal of China Pharmaceutical University, 2014, 45(2): 232-236. DOI: 10.11665/j.issn.1000-5048.20140218
[7]	DENG Danni, TIAN Hong, YAO Wenbing. Advances in therapeutic B-cell vaccines against chronic diseases[J]. Journal of China Pharmaceutical University, 2013, 44(5): 470-475. DOI: 10.11665/j.issn.1000-5048.20130517
[8]	FENG Lan-ying, HUANG Wen-ye. Expression and regulation of Bim protein in chronic myelogenous leukemia[J]. Journal of China Pharmaceutical University, 2009, 40(6): 571-575.
[9]	Effect of Amygdalin on Chronic Gastritis and Chronic Atrophic Gastritis[J]. Journal of China Pharmaceutical University, 2002, (1): 47-49.
[10]	Study on the Tolerance of the Rabbit Body Temperature Response to Bacterial Endotoxin[J]. Journal of China Pharmaceutical University, 1999, (3): 64-66.

Cited By

Get Citation

PDF

XML

Article views (798) PDF downloads (1152)

Turn off MathJax

Article Contents

Abstract

References

Immunogenicity of HER2 vaccine containing p-nitrophenylalanine

Abstract

References

Related Articles

Catalog

Immunogenicity of HER2 vaccine containing p-nitrophenylalanine

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content